KRYS vs. COOP

Last updated Jun 5, 2026

KRYS (Krystal Biotech, Inc.) and COOP (Mr. Cooper Group Inc.) are both stocks. KRYS operates in Biotechnology (Healthcare), while COOP operates in Mortgage Finance (Financial Services). At a 0.22 correlation, their price movements are largely independent.

Performance

KRYS vs. COOP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Mr. Cooper Group Inc. (COOP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

KRYS

• 1D: 1.98%
• 1M: 8.16%
• YTD: 24.84%
• 6M: 38.67%
• 1Y: 133.12%
• 3Y*: 36.21%
• 5Y*: 37.68%
• 10Y*: —

COOP

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

KRYS vs. COOP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
KRYS Krystal Biotech, Inc.	24.84%	57.37%	26.28%	56.60%	13.25%	16.58%	8.34%	166.51%	97.53%	-1.13%
COOP Mr. Cooper Group Inc.	0.00%	121.64%	47.44%	62.27%	-3.56%	34.10%	148.04%	7.20%	14.53%	-22.81%

Correlation

The correlation between KRYS and COOP is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (3Y) Calculated over the trailing 3-year period	0.26
Correlation (5Y) Calculated over the trailing 5-year period	0.25
Correlation (All Time) Calculated using the full available price history since Sep 21, 2017	0.22

The correlation between KRYS and COOP shifts across timeframes, from 0.13 (1 year) to 0.26 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap KRYS : $9.39B COOP : $13.72B
EPS KRYS : $7.50 COOP : $8.76
PE Ratio KRYS : 41.05 COOP : 24.07
PEG Ratio KRYS : 0.10 COOP : 0.24
PS Ratio KRYS : 22.13 COOP : 6.00
PB Ratio KRYS : 7.35 COOP : 2.69
Total Revenue (TTM) KRYS : $417.30M COOP : $2.29B
Gross Profit (TTM) KRYS : $387.24M COOP : $1.68B
EBITDA (TTM) KRYS : $185.45M COOP : $852.00M

Return for Risk

KRYS vs. COOP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS

KRYS Risk / Return Rank: 95
KRYS Sharpe Ratio Rank: 96
KRYS Sortino Ratio Rank: 93
KRYS Omega Ratio Rank: 93
KRYS Calmar Ratio Rank: 96
KRYS Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KRYS vs. COOP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Mr. Cooper Group Inc. (COOP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KRYS	COOP	Difference
Sharpe ratio: Return per unit of total volatility	3.45	—	—
Sortino ratio: Return per unit of downside risk	3.66	—	—
Omega ratio: Gain probability vs. loss probability	1.50	—	—
Calmar ratio: Return relative to maximum drawdown	8.40	—	—
Martin ratio: Return relative to average drawdown	21.78	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	KRYS	COOP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.45	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.50	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.64	—	—

Drawdowns

Drawdown Indicators

	KRYS	COOP	Difference
Max Drawdown Largest peak-to-trough decline	-53.42%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-15.94%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-42.26%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-44.55%	—	—
Current Drawdown Current decline from peak	-2.69%	—	—
Average Drawdown Average peak-to-trough decline	-16.21%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	6.14%	—	—

Volatility

Volatility by Period

	KRYS	COOP	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.33%	—	—
Volatility (6M) Calculated over the trailing 6-month period	27.25%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	38.86%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.43%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.22%	—	—

Dividends

KRYS vs. COOP - Dividend Comparison

KRYS has not paid dividends to shareholders, while COOP's dividend yield for the trailing twelve months is around 0.95%.

Position	TTM	2025
COOP Mr. Cooper Group Inc.	0.95%	0.95%
KRYS Krystal Biotech, Inc.	0.00%	0.00%

Financials

KRYS vs. COOP - Profitability Comparison

The chart below illustrates the profitability comparison between Krystal Biotech, Inc. and Mr. Cooper Group Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

KRYS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a gross profit of 110.03M and revenue of 116.36M. Therefore, the gross margin over that period was 94.6%.

COOP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported a gross profit of 417.00M and revenue of 608.00M. Therefore, the gross margin over that period was 68.6%.

KRYS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported an operating income of 53.69M and revenue of 116.36M, resulting in an operating margin of 46.1%.

COOP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported an operating income of 293.00M and revenue of 608.00M, resulting in an operating margin of 48.2%.

KRYS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a net income of 55.93M and revenue of 116.36M, resulting in a net margin of 48.1%.

COOP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported a net income of 198.00M and revenue of 608.00M, resulting in a net margin of 32.6%.

Frequently Asked Questions

Can I hold both KRYS and COOP in my portfolio?

KRYS and COOP have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.